INFEROPERATE
Live / Registered — Registered (as of 22 Oct 2024)
What this means for you
Registered since 22 Oct 2024. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 22 Oct 2030: the §8 declaration of use).
Record
- Serial number
- 97088778
- Registration number
- 7545192
- Mark type
- Word mark
- Filed
- 22 Oct 2021
- Published for opposition
- 06 Sept 2022
- Registered
- 22 Oct 2024
- Next maintenance filing
- §8 declaration of use, due by 22 Oct 2030 (grace period to 22 Apr 2031)
- Attorney of record
- Paulo A. de Almeida
Goods and services
- Class 009 — Scientific and electric apparatus: Downloadable cloud-computing software for clinical application or medical analysis; Downloadable computer programs using artificial intelligence for clinical application or medical analysis; Downloadable mobile applications for downloading and reading electronic publications on portable electronic devices; Downloadable virtual reality software for medical teaching; Recorded medical software for clinical application or medical analysis
Owner
- Infervision Medical Technology Co., Ltd., Beijing, CN
- Infervision Medical Technology Co., Ltd., Beijing, CN
- Infervision Medical Technology Co., Ltd., Beijing, CN
Prosecution history
- 22 Oct 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 22 Oct 2024 — REGISTERED-PRINCIPAL REGISTER
- 15 Sept 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 15 Sept 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Sept 2024 — EXAMINER'S AMENDMENT ENTERED
- 11 Sept 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 11 Sept 2024 — EXAMINERS AMENDMENT E-MAILED
- 11 Sept 2024 — SU-EXAMINER'S AMENDMENT WRITTEN
- 14 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Aug 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Aug 2024 — ASSIGNED TO LIE
- 28 Feb 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Dec 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Dec 2023 — NON-FINAL ACTION E-MAILED
- 19 Dec 2023 — SU - NON-FINAL ACTION - WRITTEN